Literature DB >> 18339372

Glucocorticoid antagonists in neuropsychiatric [corrected] disorders.

Alan F Schatzberg1, Steven Lindley.   

Abstract

Neuropsychiatric disorders often involve considerable psychological stress and elevated cortisol activity. Glucocorticoid receptors have relatively low affinity for cortisol and are found distributed throughout the brain, particularly in the frontal cortex and hippocampus. In recent years, glucocorticoid receptors antagonists have been actively studied in both animal models of several disorders as well as a potential treatment in specific types of neuropsychiatric patients. Data from these various studies are reviewed with an emphasis on seven clinical disorders or problems: major depression with psychotic features, bipolar disorder, schizophrenia, cognitive disorders, (e.g., Alzheimer's disease and mild cognitive impairment), cognitive side effects of electroconvulsive therapy, and weight gain with atypical antipsychotic agents. Potential benefits and limitations are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18339372     DOI: 10.1016/j.ejphar.2008.01.001

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  17 in total

1.  Pathophysiology of depression: do we have any solid evidence of interest to clinicians?

Authors:  Gregor Hasler
Journal:  World Psychiatry       Date:  2010-10       Impact factor: 49.548

Review 2.  Stress and neurodevelopmental processes in the emergence of psychosis.

Authors:  C W Holtzman; H D Trotman; S M Goulding; A T Ryan; A N Macdonald; D I Shapiro; J L Brasfield; E F Walker
Journal:  Neuroscience       Date:  2013-01-05       Impact factor: 3.590

3.  Decreased prefrontal cortical volume associated with increased bedtime cortisol in traumatized youth.

Authors:  Victor G Carrion; Carl F Weems; Kit Richert; Bryce C Hoffman; Allan L Reiss
Journal:  Biol Psychiatry       Date:  2010-06-26       Impact factor: 13.382

4.  Cortisol's effects on hippocampal activation in depressed patients are related to alterations in memory formation.

Authors:  Heather C Abercrombie; Allison L Jahn; Richard J Davidson; Simone Kern; Clemens Kirschbaum; Jerry Halverson
Journal:  J Psychiatr Res       Date:  2011-01       Impact factor: 4.791

Review 5.  Risk factors for development of depression and psychosis. Glucocorticoid receptors and pituitary implications for treatment with antidepressant and glucocorticoids.

Authors:  Carmine M Pariante
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

Review 6.  Glucocorticoid dysregulations and their clinical correlates. From receptors to therapeutics.

Authors:  Andrea H Marques; Marni N Silverman; Esther M Sternberg
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

7.  Psychological distress and risk for dementia.

Authors:  Martine Simard; Carol Hudon; Robert van Reekum
Journal:  Curr Psychiatry Rep       Date:  2009-02       Impact factor: 5.285

Review 8.  The molecular neurobiology of depression.

Authors:  Vaishnav Krishnan; Eric J Nestler
Journal:  Nature       Date:  2008-10-16       Impact factor: 49.962

9.  Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatment.

Authors:  Valeria Mondelli; Paola Dazzan; Nilay Hepgul; Marta Di Forti; Monica Aas; Alessandro D'Albenzio; Marco Di Nicola; Helen Fisher; Rowena Handley; Tiago Reis Marques; Craig Morgan; Serena Navari; Heather Taylor; Andrew Papadopoulos; Katherine J Aitchison; Robin M Murray; Carmine M Pariante
Journal:  Schizophr Res       Date:  2009-09-13       Impact factor: 4.939

Review 10.  Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs.

Authors:  Mark J Millan
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.